comprehensive -WSS

comprehensive

author：fashion 2025-09-27 23:53:59 - browse：7

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： When prostate cancer spreads, where it goes matters

focus

WSS

CZI to create biohub to build anti

Arc Institute generative AI designs new CRISPR systems

ADCs take center stage as promising cancer treatments

STAT Summit: Ending the crisis of Black deaths in the U.S.

HIV vaccine remains elusive. Immunologists keep trying new ideas

Wearables generate powerful data but its not useful to doctors, yet

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Drug repurposing or repositioning? The language matters

Cytokinetics CEO stresses company can launch heart drug on its own

Trump demands the U.S. pay no more for drugs than other countries … again

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Helping hospitals and community health centers plan for resilience

Duchenne breakthrough therapy leaves behind pioneering families

When prostate cancer spreads, where it goes matters

hotspot

Roivant's CEO is a star, but biotech's black hole persists

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Roivant's CEO is a star, but biotech's black hole persists

STAT Summit: Meghan O’Rourke on making chronic illness visible

Study on Amgen’s bispecific immunotherapy produces positive data

Arc Institute generative AI designs new CRISPR systems

hotspot

focus

focus

hotspot